MedTrace Logo

Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

NCT04330079 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-09-23

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of dapagliflozin therapy on myocardial perfusion reserve (MPR) using dynamic SPECT examination in prediabetic patients with stable CAD.

Dapagliflozin therapy versus lifestyle modification improves myocardial perfusion reserve in prediabetic patients with stable CAD.

Conditions

Interventions

DRUG

Dapagliflozin 10mg

Dapagliflozin 10mg once daily for 6 months.

OTHER

Lifestyle modification

lifestyle modification (diet and exercise) for 6 months

Sponsors & Collaborators

  • CHEOL WHAN LEE, M.D., Ph.D

    lead OTHER

Principal Investigators

  • Cheol Whan Lee, MD, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2021-04-08
Completion
2021-04-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04330079 on ClinicalTrials.gov